| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference:...
-
Jul 21, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the European Commission has granted Recursion Orphan...
Jun 20, 2022If successful, REC-2282 could be the first approved treatment for NF2-mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been...
-
Jun 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:
May 10, 2022Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive...